Infection

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Friday, March 1, 2024

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

Immunocore to present at upcoming investor conferences

Retrieved on: 
Friday, March 1, 2024

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Key Points: 
  • (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md., US, 01 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March:
    1x1 and small group meetings: Tuesday, March 12, 2024
    1x1 and small group meetings: Wednesday, March 13, 2024
    Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com.
  • Following the event, a replay of the presentations will be made available for a limited time.

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

Retrieved on: 
Thursday, February 29, 2024

The study revealed that complete pre-TCRα deficiency is rare in humans and less severe than anticipated.

Key Points: 
  • The study revealed that complete pre-TCRα deficiency is rare in humans and less severe than anticipated.
  • Prof. Peter Bauer, Chief Medical and Genomic Officer at CENTOGENE, said, "This research advances our understanding of pre-TCRα deficiency significantly.
  • In analyzing genomic and phenomic data, CENTOGENE researchers helped establish the association between partial pre-TCRα deficiency and autoimmunity, with a higher prevalence than initially expected.
  • Christian Beetz, Senior Director Genomic Innovation at CENTOGENE, added, “Until now, the impact of pre-TCRα deficiency has been largely unknown.

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
Thursday, February 29, 2024

The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Retrieved on: 
Thursday, February 29, 2024

The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.

Key Points: 
  • The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.
  • The event will highlight the unique predictive capabilities that differentiate the platform and how these can help address severe unmet medical needs for patients with cancer and infectious diseases.
  • The event will take place at Evaxion’s facilities in Hørsholm, Denmark, and will also be accessible via live webcast.
  • A replay of the presentations will be available on our website following the event.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.